Skip to main content

Advertisement

Table 1 Demographic and clinical characteristics of patients at the time of biopsy collection

From: Antibodies against specific extractable nuclear antigens (ENAs) as diagnostic and prognostic tools and inducers of a profibrotic phenotype in cultured human skin fibroblasts: are they functional?

Patients Subset Age (years) Gender (M/F) Disease duration (years) Autoantibody mRSS Organ involvement Therapy
1 LcSSc 57 F 12 Anti-Cenp-B 17 Lung (ILD), digital ulcers ERAs, prednisone
2 LcSSc 62 F 5 Anti-Cenp-B 4 Esophagus Ca2+ antagonists, PPIs
3 LcSSc 70 M 9 Anti-Cenp-B 14 Lung (ILD), esophagus ERAs, PPIs, MMF
4 LcSSc 67 F 10 Anti-Cenp-B 5 Esophagus Ca2+ antagonists, PPIs
5 LcSSc 48 F 8 Anti-Cenp-B 14 Lung (ILD) ERAs, Prednisone, MMF
6 LcSSc 55 F 11 Anti-Cenp-B 7 Lung (ILD) ERAs, Prednisone
7 LcSSc 58 F 13 Anti-Cenp-B 17 Lung (ILD), esophagus ERAs, PPIs, MMF
8 LcSSc 44 F 2 Anti-Cenp-B 7 Lung (PAH), esophagus Ca2+ antagonists, PPIs, prostanoids
9 LcSSc 66 F 7 Anti-Cenp-B 14 Digital ulcers esophagus ERAs, PPIs
10 LcSSc 60 F 9 Anti-Cenp-B 5 Esophagus Ca2+ antagonists, PPIs
11 DcSSc 51 F 12 Anti-Topo-I 7 Lung (PAH), digital ulcers Ca2+ antagonists, ERAs, prostanoids
12 DcSSc 72 M 11 Anti-Topo-I 17 Lung (PAH), digital ulcers ERAs, prostanoids, MMF
13 DcSSc 64 F 7 Anti-Topo-I 17 Lung (PAH), digital ulcers ERAs, prostanoids, MMF
14 DcSSc 63 M 13 Anti-Topo-I 12 Lung (ILD) ERAs, prednisone, MMF
15 DcSSc 50 F 6 Anti-Topo-I 9 Lung (ILD), esophagus Ca2+ antagonists, PPIs
16 DcSSc 68 F 15 Anti-Topo-I 14 Lung (ILD) ERAs, prednisone, MMF
17 DcSSc 59 F 14 Anti-Topo-I 17 Esophagus Ca2+ antagonists, PPIs
18 DcSSc 69 M 7 Anti-Topo-I 17 Lung (PAH) ERAs, prostanoids
19 DcSSc 49 F 9 Anti-Topo-I 14 Lung (PAH), esophagus ERAs, prostanoids, PPIs
20 DcSSc 61 F 11 Anti-Topo-I 17 Lung (ILD), esophagus Ca2+ antagonists, PPIs, MMF
  1. Abbreviations: Cenp-B centromeric protein B, ERAs endothelin receptor antagonists, ILD interstitial lung disease, MMF mycophenolate mofetil, mRSS modified Rodnan skin score, PPIs proton pump inhibitors, PAH pulmonary arterial hypertension, Topo-I topoisomerase I